Volume 14, Number 6—June 2008
Managing Potential Laboratory Exposure to Ebola Virus by Using a Patient Biocontainment Care Unit1
|Patient no.||Date of admission||Days in isolation||Virus†||Reason for admission||Therapy‡||Comments§|
|1||1972 Oct||18||Machupo||Cut finger||IP|
|2||1975 Oct||42||Machupo||Cut finger||IP, IG|
|4||1977 Sep||14||Machupo||Vial leak|
|5||1977 Sep||14||Machupo||Vial leak|
|6||1978 May||11||Dengue||Not specified||Modified CC|
|7||1978 May||8||Dengue||Not specified||Modified CC|
|8||1978 Jun||17||Lassa||Dropped vial||LIG|
|9||1978 Jun||17||Lassa||Dropped vial||LIG|
|10||1978 Jul||8||Lassa||Field exposure|
|11||1978 Nov||14||Lassa||Suit seam failed|
|14||1979 Nov||20||Lassa||Fingerstick||IP, Rib|
|15||1981 May||14||Ebola/Lassa||Field exposure||Modified CC|
|16||1982 Oct||14||Junin||Defective suit seal||Conventional|
|18||1983 Jan||3||Rift Valley fever||Waste exposure|
|19||1983 Apr||14||Junin||Defective suit seal||Conventional|
*Modified from Cieslak et al. (8) with permission.
†JEB, Japanese encephalitis virus B; Ebola/Lassa, potential exposure to these viruses.
‡IP, immune plasma from previously infected survivors; IG, immune globulin; LIG, Lassa immune globulin; Rib, ribavirin.
§CC, containment care; modified CC, provided by converting a separate physical facility into a Biosafety Level 4–like suite; conventional, Biosafety Level 3 isolation was permitted for 2 lower risk exposures.
¶Not noted in previous reports (7,8).
- Centers for Disease Control and Prevention and National Institutes of Health. Biosafety in microbiological and biomedical laboratories (BMBL). 5th ed. Washington: US Government Printing Office; 2007 [cited 2007 Aug 27]. Available from http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm
- Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol. 2001;125:243–53.
- Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391–404.
- National Briefing/Science and Health. Scientist is isolated after scrape with Ebola. New York Times. 2004 Feb 20 [cited 2007 Aug 27]. Available from http://www.nytimes.com/ref/membercenter/nytarchive.html
- Babiarz L. Detrick’s “slammer” prepared for worst. Frederick News. 2004 Mar 16:A1.
- Preston R. The hot zone. New York: Doubleday; 1994.
- Marklund LA. Patient care in a biological safety level–4 (BSL-4) environment. Crit Care Nurs Clin North Am. 2003;15:245–55.
- Cieslak TJ, Christopher GW, Eitzen EM. The “slammer”: isolation and biocontainment of patients exposed to Biosafety Level 4 (BSL-4) pathogens. In: Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA; 1999 Nov 18–21. Abstract 693. Alexandria (VA): Infectious Diseases Society of America; 1997.
- Luby JP, Sanders CV. Green monkey disease (“Marburg virus” disease): a new zoonosis. Ann Intern Med. 1969;71:657–60.
- Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. BMJ. 1977;2:541–4.
- Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d’Ivoire: clinical and biologic presentation. J Infect Dis. 1999;179:S48–53.
- Miller J. Russian scientist dies in Ebola accident at former weapons lab. New York Times. 2004 May 25.
- Rusnak JM, Kortepeter MG, Aldis J, Boudreau E. Experience in the medical management of potential laboratory exposures to agents of bioterrorism based on risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). J Occup Environ Med. 2004;46:791–800.
- Rusnak JM, Kortepeter MG, Hawley RJ, Boudreau E, Aldis J, Pittman PR. Management guidelines for laboratory exposures to agents of bioterrorism. J Occup Environ Med. 2004;46:801–11.
- Rusnak JM, Kortepeter MG, Ulrich R, Poli M, Boudreau E. Laboratory exposures to staphylococcal enterotoxin B. Emerg Infect Dis. 2004;10:1544–9.
- Rusnak J, Boudreau E, Bozue J, Petitt P, Ranadive M, Kortepeter M. An unusual inhalational exposure to Bacillus anthracis in a research laboratory. J Occup Environ Med. 2004;46:313–4.
- Peters CJ. Marburg and Ebola virus hemorrhagic fevers. In: Mandell GL, Bennett JE, Dolin R., editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 2057–60.
- Smith PW, Anderson AO, Christopher GW, Cieslak TJ, Devreede GJ, Fosdick GA, Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosecur Bioterror. 2006;4:351–65.
- Centers for Disease Control. Management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep. 1988;37(Suppl 3):1–16.
- Centers for Disease Control and Prevention. Update: management of patients with suspected viral hemorrhagic fever—United States. MMWR Morb Mortal Wkly Rep. 1995;44:475–9.
- Centers for Disease Control and Prevention. Interim guidance for managing patients with suspected viral hemorrhagic fever in U.S hospitals [cited 2006 Nov 15]. Available from http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html
- Stephenson EH, Larson EW, Dominik JM. Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol. 1984;14:295–303.
- Armstrong LR, Dembry LM, Rainey PM, Russi MB, Khan AS, Fischer SH, Management of a Sabia virus-infected patient in a U.S. hospital. Infect Control Hosp Epidemiol. 1999;20:176–82.
- Centers for Disease Control and Prevention. Severe acute respiratory syndrome: fact sheet on legal authorities for isolation and quarantine [cited 2007 Aug 27]. Available from http://www.cdc.gov/ncidod/sars/factsheetlegal.htm
- Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953–8.
- Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr Med Chem. 2005;12:2193–214.
- Warfield KL, Swenson DL, Olinger GG, Nichols DL, Pratt WD, Blouch R, Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006;2:e1.
- Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-Dicaprio K, Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006;193:1650–7.
- Nabel NJ, Sanchez A, Rollin PE, Yang ZY, Nable GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–9.
- Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Accelerated vaccination for Ebola virus hemorrhagic fever in non-human primates. Nature. 2003;424:681–4.
- Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006;3:e177.
- Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–77.
- Lawler A. Boston University under fire for pathogen mishap. Science. 2005;307:501a.
- Barry MA. Report of pneumonic tularemia in three Boston University researchers, November 2004–March 2005 [cited 2007 Aug 27]. Available from http://www.bphc.org/reports/pdfs/report_202.pdf
1This article is derived from the lecture “10 Steps in Managing an Ebola Exposure,” presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, December 15, 2005, Washington, DC, USA, and September 26, 2006, San Francisco, CA, USA.